Close

Epstein-Barr Virus (EBV)

Epstein–Barr virus (EBV), also called human herpesvirus 4 (HHV-4), is a virus of the herpes family and infects more than 95% of the world’s population. The most common disease from primary infection is acute infectious mononucleosis, a self-limiting illness that frequently affects adolescents and young adults.

Have questions about a product?

Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!

Contact A Specialist
Filter By:
Clear Results
17 Results
Name
Type
Format
Host/Source
Isotype
Tested Apps
Unit
Catalog
SDS
COA
Request Sample
EBV EBNA-1, Recombinant
Antigen, Other
Purified
E. coli
N/A
CLIA, EIA, WB
MG
R01672
EBV-vca Gp125, Purified Ag
Antigen, Other
Purified
Cell Culture
N/A
CLIA, EIA, LF, WB
ML
8202
EBV P54 (ea-d) Recombinant
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R01575
MAb to Epstein Barr Virus
Monoclonal
Purified
Mouse
IgG1
IFA
MG
C65023M
MAb to Epstein Barr Virus
Monoclonal
FITC
Mouse
IgG1
IFA
MG
C65223M
MAb to Epstein Barr Virus
Monoclonal
Purified
Mouse
IgG1
IFA, WB
MG
C65221M
EBV Vca P23 Recombinant
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R01570
EBV Vca P18 Recombinant
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R01571
MAb to Epstein Barr Virus
Monoclonal
Purified
Mouse
IgG1,k
EIA, IFA, WB
MG
C66405M
MAb to EBV EA-R
Monoclonal
Purified
Mouse
IgG1
EIA, IHC(p), IP, WB
MG
C65502M
MAb to Epstein Barr Virus
Monoclonal
Purified
Mouse
IgG2
IFA, IHC, WB
MG
C65026M
Goat anti EBV Nuclear antigen
Polyclonal
Purified
Goat
N/A
EIA, IFA
ML
B65102G
EBV (HHV-4) P23, Recomb.
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R18230
EBV (HHV-4) Ea-d Recombinant
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R18740
EBV P138 (ea-d) Recombinant
Antigen, Other
Purified
E. coli
N/A
EIA, WB
MG
R01525
EBV Ebna-1, Recombinant
Antigen, Other
Purified
E. coli
N/A
CLIA, EIA, WB
MG
R01522
EBV antigen P3h3
Antigen, Other
Lysate
P3H3 Cells
N/A
EIA
ML
R02100

Epstein-Barr Virus (EBV)

Primary EBV infections are typically asymptomatic and it is perhaps the most common reason for fever of unknown origin in young children. It does not occur in epidemics and has relatively low transmissibility, spreading mainly through bodily fluids (saliva). Approximately 90% of the US population is infected with EBV by the age of 25 and this infection rate is similar in other developed countries worldwide. EBV during pregnancy and transplacental transmission is rare. When infection with EBV occurs during adolescence or young adulthood, it causes infectious mononucleosis 35% to 50% of the time.

EBV is the first human virus to be directly implicated in carcinogenesis. Infection is associated with particular forms of cancer, such as Hodgkin’s lymphoma, Burkitt’s lymphoma, nasopharyngeal carcinoma, and conditions associated with AIDS including hairy leukoplakia and central nervous system lymphomas. In particular in Africa, the virus is associated with endemic Burkitt lymphoma in the setting of co-infection with Plasmodium falciparum. Specifically, it has been found that a malaria infection can impair the T-cell response to EBV and directly contribute to tumor pathogenesis.

Diagnosis

Diagnosing an EBV infection can be challenging since the symptoms are similar to other illnesses. However, different proteins are expressed during the various stages the EBV life cycle and the detection of these antigens can help distinguish whether an infection is a primary acute, convalescent, latent, or reactivation infection. About 90% of adults have antibodies that show that they have a current or past EBV infection. Diagnostic methods for EBV include IFA, ELISA, blot techniques, IgG avidity, PCR and virus isolation. Tests are available for detecting antibodies to the following EBV-associated antigens:

Viral capsid antigen (VCA):

  • Elevated anti-VCA IgM indicates acute infection (appears early in infection and usually disappears within 4 – 6 weeks)
  • Elevated anti-VCA IgG indicates prior infection (appears in the acute phase, peaks 2-4 weeks after onset, declines slightly, then persists for the rest of a person’s life)
  • Common VCA proteins are gp125 and p19

Early antigen (EA)

  • Anti-EA IgG appears in the acute phase of illness and generally falls to undetectable levels after 3-6 months
  • In many people, detection of antibody to EA is a sign of an active infection
  • 20% of healthy people may have antibodies against EA for several years

EBV nuclear antigen (EBNA)

  • Antibody to EBNA is not seen in the acute phase of EBV infection but slowly appears 2-4 months after onset of symptoms
  • Persists for the rest of a person’s life

Get In Touch With A Specialist

Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!

By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our Privacy Statement.

Learn More About Us

Learn More

Welcome to

Please select your country to continue

Continue
EN